secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0000950170-23-025321
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics shareholders elect three directors, approve executive pay and auditor at 2023 annual meeting
--------------------------------------------------------------------------------

- Douglas S. Ingram, Sekar Kathiresan, and Jami Rubin elected as Class III directors with 103.3M, 104.6M, and 94.8M votes for, respectively.
- Non-binding advisory vote on executive compensation approved: 97.8M for, 6.9M against, 70k abstained.
- Ratification of Ernst & Young as independent auditor for FY2023: 112.2M for, 11.6k against, 40k abstained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023025321/0000950170-23-025321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023025321/rlay-20230531.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-025321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer